La chaîne d'options affiche les données clés des options sur actions de Axion Ven à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Axion Ven..

Axion Ven (OTC:AXNVF) Stock, Chaîne d'Options

Axion Ventures Inc is an investment issuer with majority ownership in online video gaming and other IT sectors. The principal activities of the Group are principally engaged in game software development, game operation, provision of outsourcing services, software license and software training. The geographical presence of the company in Canada, China and Rest of the world.

AXION VENTURES INC by Axion Ventures Inc.

Axion Ventures Inc

WIIM

AUB stock has given up its prior gain. Atlantic Union shares were trading higher after the company announced it closed a $2 billion CRE loan sale to Blackstone.

News

WERN

Texas Supreme Court Reverses And Dismisses $90M Truck Crash Verdict Against Werner Enterprises

MRC Global shares are trading higher after the company announced it will be acquired by DNOW as part of a definitive merger agreement. Also, Stifel raised its price target on the stock from $15 to $17.

<a href="https://www.bloomberg.com/news/articles/2025-06-27/total-gets-offers-for-potential-sale-of-argentina-shale-oil-assets?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-27/total-gets-offers-for-potential-sale-of-argentina-shale-oil-assets?embedded-checkout=true</a>

General

'Total Gets Offers for Potential Sale of Argentina Shale Oil Assets'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-27/gop-reaches-tentative-salt-deal-at-40-000-cap-five-year-limit?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-27/gop-reaches-tentative-salt-deal-at-40-000-cap-five-year-limit?embedded-checkout=true</a>

'GOP Reaches Tentative SALT Deal at $40,000 Cap, Five-Year Limit'- Bloomberg

Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) postponed the commercialization of its in-house next-gen <a target="_blank" href="https://www.benzinga.com/topic/chip-stocks" rel="noreferrer noopener">artificial intelligence chip</a>, Maia (code-named Braga), by at least six months from 2025 to 2026 due to unexpected changes to its design and staffing constraints.
There were also concerns over the chip lagging behind Nvidia Corp.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell chip that hit the market in 2024, Reuters reported on Friday, citing the Information.
Microsoft introduced the Maia chip in <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/35820417/cramer-says-microsoft-simply-cant-compete-with-nvidia-after-software-giant-launches-in-house-ai-" rel="noreferrer noopener">November 2023</a>, but unlike its competitors, the company has struggled to ramp up production.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/46111075/microsofts-new-ai-lab-powers-wisconsin-manufacturing" rel="noreferrer noopener">Microsoft&#8217;s New AI Lab Powers Wisconsin Manufacturing</a>
Cloud rivals like Amazon.Com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) (with its <a target="_blank" href="https://www.benzinga.com/media/24/12/42356920/amazon-halts-inferentia-ai-chip-development-to-take-on-nvidia-how-trainium-is-shaping-up-to-be-the-new-weapon-in-ai-chip-wars" rel="noreferrer noopener">Trainium3</a> chip) and Alphabet Inc.&#8217;s Google (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (with its Tensor Processing Units) have made more significant strides in in-house chip development and deployment.
These advancements by rivals underscore the intense competition among tech giants to develop custom AI processors, aiming to optimize performance and reduce reliance on external suppliers like Nvidia, thereby reducing costs.
In 2024, Microsoft reportedly <a target="_blank" href="https://www.benzinga.com/tech/24/12/42547442/microsof-scoops-up-485000-nvidia-ai-chips-twice-as-many-as-its-closest-rival-meta-report" rel="noreferrer noopener">purchased close to</a> 485,000 Nvidia &#8220;Hopper&#8221; AI chips, beating Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), which procured 224,000&nbsp;chips.
For context on Nvidia&#8217;s dominant position and financial performance, the company reported <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45657660/nvidia-q1-highlights-china-export-ban-hits-results-but-jensen-huang-says-demand-incredibly-strong" rel="noreferrer noopener">first-quarter revenue</a> of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter.
The revenue beat a Street consensus estimate of $43.2 billion. Nvidia faced an export ban on H20 products to China on April 9, prompting it to book a $4.5 billion charge in the first quarter.
Still, Nvidia guided for second-quarter revenue of $45.0 billion, +/- 2%. The guidance includes the loss of $8.0 billion in H20 revenue due to the export controls.
Barclays projected Nvidia to <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45992099/nvidia-stock-could-rise-another-38-making-jensen-huang-led-ai-giant-a-nearly-5-trillion-company-says-barclays" rel="noreferrer noopener">reach a market cap</a> of $5 trillion backed by AI market leadership, growing opportunities in&nbsp;sovereign AI, and the Blackwell AI platform.
In June, Nvidia overtook Microsoft to become the world&#8217;s most valuable&nbsp;publicly traded&nbsp;company, with a market cap of $3.4 trillion.
Price Actions: MSFT stock is trading higher by 0.10% to $497.98 at last check Friday. NVDA is up 1.49%.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/06/46040754/amazons-powerful-aws-custom-chip-to-get-an-upgrade-why-is-it-important" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Powerful AWS Custom Chip To Get An Upgrade &#8211; Why Is It Important?</a></li>
</ul>
Photo via Shutterstock

Tech

Media

AMZN

GOOG

GOOGL

MSFT

NVDA

Microsoft's Next-Gen AI Chip Still Lags Nvidia's Blackwell, Postpones Launch

FICO

FNMA

Shares of credit bureau companies are trading lower after U.S. Director of Federal Housing FHFA Bill Pulte said "We are doing a full scale review of all credit bureaus."

Ascent Solar Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) ("Ascent" or the "Company"), the leading U.S. innovator in the design and manufacture of featherweight, flexible, and durable CIGS thin-film photovoltaic (PV) solutions, today announced the pricing of a public offering of an aggregate of 1,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 1,000,000 shares of common stock (the "Warrants"), at a combined public offering price of $2.00 per share (or per pre-funded warrants in lieu thereof) and accompanying Warrant. The Warrants will have an exercise price of $2.00 per share, will be exercisable immediately upon issuance, and will expire on the five-year anniversary of the initial issuance date. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions.
H.C. Wainwright &amp; Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be $2.0 million before deducting the placement agent's fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, product development activities, general and administrative expenses and other general corporate purposes.

Offerings

ASTI

Ascent Solar Prices $2M Public Offering of 1M Shares and 1M Warrants At A Combined Price Of $2.00

You may not have noticed, but on Sunday, June 22, the world of cars changed forever. 
That was when regular consumers for the first time got to take a $4.20-ride around Austin, Texas, in driverless taxis, courtesy of Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Elon Musk.
The <a href="https://www.benzinga.com/markets/tech/25/06/46045542/tesla-launches-robotaxi-in-austin-elon-musk-calls-it-a-culmination-of-a-decade-of-hard-work">robotaxi test</a> took place in a sectioned, geofenced area of Austin, with selected Tesla owners in the back seat, a Tesla employee on hand for emergencies in the front passenger seat, and no one physically behind the wheel.
By the end of the day, feedback began rolling in on social media, and it was overwhelmingly positive.
"We took two approximately 15-minute rides around Austin and the key takeaways are that it was a comfortable, safe, and personalized experience," <a href="https://www.benzinga.com/markets/tech/25/06/46049232/dan-ives-hails-very-impressive-robotaxi-ride-in-austin-predicts-55-upside-for-tesla-stock-as-golden-age-begins">noted</a> Dan Ives, a Wedbush analyst, in a research note released later in the day on June 22.  
"The robotaxis we experienced today were foundational, and there is a path for the future where these robotaxis may also have Grok integration, interior customization, and a much more user-centric focus as there&#8217;s no longer a need to focus on the driver experience," Ives added.
He&#8217;s not alone.
"Today transportation changed FOREVER!" said<a href="https://x.com/JoshWest247/status/1932618098777137590"> JoshWest247 on X</a>, after his test drive. "Robotaxi=FREEDOM!"
Amidst talk of the Tesla robotaxi adding $1 trillion in value to the company, plans are afoot to manage vehicle growth gradually, with 50 in operation by the fourth quarter of 2025 in Austin and 1,000-plus on the streets by year-end 2026. Tesla is also mapping out a California robotaxi expansion, targeting 2026, pending approval from the state. Over time, Tesla aims to replace Model Ys with its Cybercab robotaxi vehicle.
At first glance, the driverless future is golden, although there's plenty of highway miles ahead for industry leaders. At the very least, the Austin tests may serve as the launch point of a revolutionary new industry that changes everything we think we know about road transportation.
"Tesla's autonomous taxi test in Austin signals a very real shift toward mainstream adoption of robotaxis, not just a speculative future," said Kazimieras Urbonas, car analyst and supplier excellence manager at Ovoko, a technology-based auto parts company. "The major takeaway is that we're no longer just talking about autonomy, we're piloting it at scale. This shows growing maturity in Tesla's FSD (Full Self-Driving) tech, which will inevitably pressure other automakers to speed up their timelines."
According to Urbonas, driverless transport will be one of the most transformative changes in mobility, comparable to the transition from combustion to electric power. "While rollout will vary by region due to infrastructure and legal constraints, the long-term implications for logistics, ride-hailing, and even public transport are enormous," he noted. "Think safer roads, lower costs, and new urban design models."
As the smoke cleared from the test date, Wall Street commenced buzzing over the trading prospects of autonomous vehicle makers and which companies may be left behind as history is made with the first driverless taxi rollout.
<h2 class="wp-block-heading">Independence From Trading Tool Chaos</h2>
Stop switching between news apps, scanners, and alert systems that don't communicate with each other. Get our exclusive Benzinga Wire, smart filtering, and integrated tools in one professional platform. Declare Trading Independence <a href="https://www.benzinga.com/pro/register/4th-of-july-sale/?utm_campaign=bzpro-4th&amp;el=Res[…]mail}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD062825">HERE</a> at 60% off.
Which stocks will rock on as robotaxis get all too real, and which will go the way of horse and carriage after Henry Ford rolled up in a small, four-wheeled vehicle he called a Quadricycle on June 4, 1896? Here are a few candidates on both sides of the road.
<h2 class="wp-block-heading">Winners</h2>
<h3 class="wp-block-heading">Tesla</h3>
Benzinga Quality Ranking: 83.17
The carmaker's share price only popped by 1.2% in the five days following the Austin robotaxi tests, but the moment may have established Tesla as the king of the driverless transport hill, for now at least. Tesla has a lot on the line with autonomous vehicles, which comprises about 59% of the company's price target, amounting to $181 per share or $800 billion in implied value, according to RBC Capital.
"If Tesla can iron out safety concerns and scale fast, they could dominate the driverless car industry," said John Ellmore, EV Fleet Editor at UK-based KnowYourBusiness.
<h3 class="wp-block-heading">Alphabet&nbsp;</h3>
Benzinga Quality Ranking: 86.66
Google's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Waymo driverless taxi doesn't get the massive press that Tesla and Musk garner, but it's actually ahead of the curve on robotaxi testing. It's already up and running in four U.S. cities, with plans to roll out its autonomous vehicles in 17 more. It intends to launch commercially by 2026 or 2027. All told, Waymo is expected to account for 10% of the AV marketplace by the end of the decade.
<h3 class="wp-block-heading">Nvidia</h3>
Benzinga Growth Ranking: 98.61
Chipmaking giant Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) should benefit from the headway made by companies like TSLA and Waymo. "Nvidia's chips already power most autonomous driving systems," Urbonas said. "More driverless vehicles equal more demand."
<h2 class="wp-block-heading">Losers</h2>
<h3 class="wp-block-heading">Uber</h3>
Benzinga Growth Ranking: 97.49
Uber's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) stock hasn't suffered from Tesla's wave of media coverage following its Austin testing weekend – it's up 8.36% this week alone. Analysts point to Uber's burgeoning relationship with Waymo and the fact that the company has entered into AV testing with Volkswagen and Pony AI.
Yet over the long haul, Uber doesn't seem to have a clear-cut path in competing with driverless taxis, which promise to be cheaper and more pervasive once Tesla and Waymo vehicles hit the open road.
<h3 class="wp-block-heading">Lyft</h3>
Benzinga Growth Ranking: 56.43
San Francisco-based ride-sharing company Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) has seen its shares rise to the mid-teens (it was trading at $15.46 on June 27). Its stock is up 19% year-to-date. The firm plans to roll out its own AV line in Dallas over the next few months, with plans to expand to Canada and Europe the following year.
Still, the math is working against Lyft. It's already behind Uber in the rideshare market by a 30%-to-70% ratio. The company will be hard-pressed to compete with industry heavyweights like Tesla, which is expected to reach a $1 trillion market share within the next five years.
"Traditional ride-hailing platforms like Uber and Lyft could see margin compression as autonomous fleets reduce human labor costs," Urbonas added.
<h3 class="wp-block-heading">Traditional auto makers and auto parts companies</h3>
Legacy automakers without robust EV and autonomous vehicle pipelines could fall behind. 
"That's particularly the case with those companies reliant on fleet sales and dealer-driven models," Urbonas said. "Auto parts suppliers focused on mechanical components (e.g., internal combustion parts) could also struggle as electric-autonomous systems reduce part complexity and maintenance."
Traditional auto repair chains could also struggle, and they won't be alone.
"Fewer moving parts mean fewer breakdowns," said Luis Montes, a heavy-duty transport equipment expert and chief editor at Fortis HD.  "Fuel providers take a hit if the shift is electric-heavy. Public transport might also lose funding if private driverless fleets get political backing. Even parking real estate will lose relevance if cars start circulating instead of idling."
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

Trading Ideas

LYFT

TSLA

UBER

Winning And Losing Stocks From Tesla's Driverless Taxi Test

ABAT

American Battery Technology To Be Added To Russell 2000 And Russell 3000 Indexes, Effective June 30, 2025

U.S. Senator Maggie Hassan (D-NH) is intensifying her scrutiny of GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) over the company's decision to pull its widely used asthma inhaler, Flovent HFA, from the market.
One year after the discontinuation, Hassan launched a formal investigation into the move, raising alarms about patient access, skyrocketing costs, and the financial burden placed on Medicaid.
Flovent HFA had long been the most <a target="_blank" href="https://www.hassan.senate.gov/news/press-releases/senator-hassan-launches-investigation-into-gsk-on-impact-of-its-discontinuation-of-childrens-asthma-inhaler" rel="noreferrer noopener">prescribed</a> controller inhaler for young children with asthma. After it was removed from the market in January 2024, GSK partnered with Prasco Laboratories to distribute an authorized generic version.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45406673/gsk-to-buy-phase-3-ready-liver-disease-drug-for-up-to-2-billion" rel="noreferrer noopener">GSK To Buy Phase-3 Ready Liver Disease Drug For Up To $2 Billion</a>
This rebranded product has been significantly more expensive for patients, allowing GSK to avoid an estimated $367.6 million in Medicaid rebates in 2024 alone. Instead, Medicaid spent over $550 million on the authorized generic in 2024.
In a <a target="_blank" href="https://www.hassan.senate.gov/imo/media/doc/2025-06-27%20Hassan%20to%20GSK%20-%20Copy_Redacted.pdf" rel="noreferrer noopener">letter</a> to the CEO, Emma Walmsley, Senator Hassan criticized the maneuver as a corporate strategy that prioritized profits over patients, stating that it threatened the lives of children and placed undue financial strain on families. "GSK's decision to allow a different company to sell the same product in a more expensive form has endangered children and fleeced taxpayers," she said.
Hassan <a target="_blank" href="https://www.hassan.senate.gov/news/press-releases/senator-hassan-presses-big-pharma-company-to-restore-access-to-low-cost-asthma-inhalers-for-children" rel="noreferrer noopener">urged</a> GSK to restore the original Flovent HFA and work with Prasco to reduce the cost of the generic version.
In her May 2024 letter, Hassan questioned why GSK discontinued Flovent HFA while keeping other brand-name inhalers on the market and capping their prices. GSK's response did not clarify this; instead, it shifted responsibility to Prasco for pricing decisions and formulary negotiations.
While GSK claimed the generic was priced 35% lower than branded Flovent, previous rebates on the original product had made it significantly more affordable. The absence of such rebates for the generic has led many insurers and pharmacy benefit managers to delay or deny coverage.
The consequences have been severe. Pediatric providers reported that Flovent HFA was the only inhaler compatible with spacer devices for infants and young children.
Its removal has limited treatment options, especially for patients with eosinophilic esophagitis or those who cannot tolerate alternatives. Meanwhile, other substitute inhalers, like Asmanex HFA and Alvesco, have faced shortages or limited insurance coverage throughout 2024.
A study published in October 2024 revealed a 17.5% increase in asthma-related hospitalizations in the three months after Flovent's removal, followed by a 24.1% increase over the next three to six months compared to previous years. ICU admissions showed similar spikes.
Beyond health outcomes, the financial impact has been substantial. A Johns Hopkins analysis found that Medicaid spent an estimated $551.8 million on the authorized generic in 2024 — nearly double what it might have spent under the original rebate structure. Even insured patients reported paying up to $150 per inhaler.
Senator Hassan's investigation aims to hold GSK accountable and prevent similar corporate tactics that bypass rebate obligations at the expense of public health.
Price Action: GSK stock is trading lower by 0.03% to $38.54 at the last check Friday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/upgrades/25/06/46146899/this-is-googles-secret-weapon-to-outpace-chatgpt-in-the-search-war" target="_blank" rel="noreferrer noopener">This Is Google's Secret Weapon To Outpace ChatGPT In Search War</a></li>
</ul>
Photo via Shutterstock

Government

Large Cap

Legal

GSK Rebranded Flovent Asthma Inahler For Children To Avoid $367 Million Medicaid Rebate, Senator Hassan Accuses

<a href="https://x.com/pulte/status/1938659666885779503" rel="noopener noreferrer" target="_blank">https://x.com/pulte/status/1938659666885779503</a>
&nbsp;
<a href="https://x.com/pulte/status/1938659896024551438" title="https://x.com/pulte/status/1938659896024551438">https://x.com/pulte/status/1938659896024551438</a>

Politics

FMCC

U.S. Director of Federal Housing FHFA Bill Pulte Posts On X "We are doing a full scale review of all credit bureaus.", On High Interest Rates Says "It's not just people's mortgages. It's car loans, credit cards, etc. These decisions have real impacts on real people."

U.S. President Donald Trump said Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is helping relieve pressure on the U.S. dollar, calling its increasing adoption "<a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46131815/trumps-crypto-advisor-david-sacks-says-july-will-be-a-big-month-says-president-supports-legislation-on-market-structure-and-stablecoins">a great thing for our country</a>."
Speaking about the evolving role of Bitcoin in the economy, Trump said that more people are using it for payments and that the digital asset has become an important part of the financial system.
"I noticed more and more you're paying Bitcoin," Trump said. "People are saying it takes a lot of pressure off the dollar. And it's a great thing for our country."
Trump clarified that he does not personally invest in Bitcoin, but said, "I have my kids and they invest in different things. They do believe in it." 
His comment aligns with the known fact that members of the Trump family have been publicly supportive of cryptocurrencies.
In particular, his son Eric Trump has emerged as a prominent advocate for Bitcoin. 
Eric has regularly spoken at crypto conferences and is involved in American Bitcoin, a company closely aligned with the Trump family that focuses on Bitcoin infrastructure and mining. 
Additionally, Trump Media &amp; Technology Group, linked to the former president, announced earlier this year that it planned to allocate billions of dollars toward Bitcoin as part of its treasury strategy.
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46146124/bitcoin-yields-of-up-to-8-are-no-longer-a-fantasy-heres-whos-offering-them">Bitcoin Yields Of Up To 8% Are No Longer A Fantasy: Here&#8217;s Who&#8217;s Offering Them</a>
Trump emphasized that his role as president contributed to building an industry that has become strategically significant for the country. "What I did do there is build an industry that's very important," he said.
He also pointed out the geopolitical importance of the U.S. embracing crypto. "You know, we didn't have a [crypto] industry, China would," Trump said.
The Trump family has heavily invested in cryptocurrencies. 
Trump Media and Technology Group, the parent company of Truth Social, announced in May 2025 a $2.5 billion raise to create a &#8220;Bitcoin treasury.&#8221; 
The company, where Trump holds a 53% stake, aims to diversify its $700 million cash reserves into crypto assets, including exchange-traded funds like the proposed "Truth.fi Bitcoin Plus ETF." 
Additionally, American Bitcoin, a mining firm co-founded by Eric Trump and backed by Donald Trump Jr., merged with Gryphon Digital Mining to go public on Nasdaq in 2025. 
The family also holds a 60% stake in World Liberty Financial, which launched a stablecoin, USD1, and raised $550 million in token sales, including a $2 billion investment from an Abu Dhabi-based firm.
Trump's pro-crypto policies include an executive order signed in March 2025 to establish a Strategic Bitcoin Reserve and a Digital Assets Stockpile, aiming to position the U.S. as the "crypto capital of the world." 
His administration has paused a dozen federal crypto probes and dropped lawsuits against crypto firms, reversing Biden-era regulations. 
However, these moves have sparked concerns about conflicts of interest, with critics like Sen. Elizabeth Warren (D-Mass.) accusing Trump of "crypto corruption" due to his family's financial stakes.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46140769/north-korean-hackers-top-crypto-exploits-list-but-another-state-may-surprise-you">North Korean Hackers Top Crypto Exploits List, But Another State May Surprise You</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Donald Trump Says 'Bitcoin Takes A Lot Of Pressure Off The Dollar'

KTOS

Kratos Defense & Security shares are trading higher after Truist Securities raised its price target on the stock from $38 to $52.

Lottery.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRY#NASDAQ">LTRY</a>, LTRYW))) ("Lottery.com" or "the Company"), a leading technology company transforming the intersection of gaming, sports and entertainment, today confirmed that it is nearing legal proof of a coordinated and unlawful ‘short and distort' campaign targeting the Company. In collaboration with its legal counsel, Paul Hastings LLP, the Company is actively pursuing all individuals and entities engaged in market manipulation intended to damage the Company's share price and reputation.
Christopher Gooding, Independent Director of Lottery.com and a member of the Audit Committee with responsibility for legal affairs, issued the following statement:
"There is no doubt that there is an orchestrated campaign against Lottery. The trading metrics and forensic data we have access to clearly indicate both classic ‘short and distort' tactics, and more seriously, a significant volume of naked short selling — illegal trades not backed by actual share ownership.
"These actors fall into three categories:
<ul>
<li>"Aggressive and embittered insiders, who appear to be leveraging confidential or insider information from their historical relationships with Lottery.com for self-serving purposes. I outlined elements of these insiders to the judge in a Delaware action earlier this year;</li>
<li>"Professional short-sellers, aided and abetted by complicit brokers — some of whom are actively engineering mechanisms to facilitate, or are willfully ignoring, illegal naked short activity; and</li>
<li>"Opportunistic traders, influenced by blogs, shorting platforms, and "pay-to-publish" media articles that amplify false and defamatory narratives. These clearly represent the ‘distort' component of the campaign. Numerous cease-and-desist letters have already been issued. "Our message to these parties is unequivocal: We know who you are. We are rapidly securing irrefutable legal evidence of your involvement — including the brokers operating both in the U.S. and offshore in jurisdictions such as the Caribbean. We will pursue damages vigorously and refer the evidence to the appropriate regulatory authorities. "Your days are numbered. We will shut you down, and the financial penalties imposed will far exceed the unlawful profits you have sought to extract from our shareholders." &nbsp;</li>
</ul>
Lottery.com reiterates its commitment to protecting shareholder value, market integrity, and the long-term growth of its global operations.

Short Sellers

LTRY

Lottery.com Alleges Coordinated Illegal 'Short and Distort' Campaign, Vows Legal Action Against Market Manipulators, Says ""There Is No Doubt That There Is An Orchestrated Campaign Against Lottery. The Trading Metrics And Forensic Data We Have Access To Clearly Indicate Both Classic 'Short And Distort' Tactics, And More Seriously, A Significant Volume Of Naked Short Selling.."

Analysts' ratings for Autodesk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) over the last quarter vary from bullish to bearish, as provided by 27 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">14</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">8</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $336.0, a high estimate of $376.00, and a low estimate of $265.00. Surpassing the previous average price target of $329.63, the current average has increased by 1.93%.
<img src="https://www.benzinga.com/files/images/story/2025/1751047308_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Autodesk among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nay Soe Naing</td>
<td>Berenberg</td>
<td>Raises</td>
<td>Buy</td>
<td>$365.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$376.00</td>
<td>$374.00</td>
</tr>
<tr>
<td>Clarke Jeffries</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$361.00</td>
<td>$357.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$345.00</td>
<td>$313.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$360.00</td>
<td>$345.00</td>
</tr>
<tr>
<td>Michael Funk</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$330.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Daniel Jester</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$333.00</td>
<td>$324.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$355.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$370.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$323.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$305.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$345.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$374.00</td>
<td>$346.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$340.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$335.00</td>
<td>$303.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$345.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$330.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Jason Celino</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$323.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$350.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>William Jellison</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$265.00</td>
<td>$285.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$325.00</td>
<td>$365.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$310.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Stephen Tusa</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$280.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Ken Wong</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$300.00</td>
<td>$350.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Autodesk. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Autodesk compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Autodesk's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Autodesk's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADSK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Autodesk analyst ratings.</a>
<h2>About Autodesk</h2>
Founded in 1982, Autodesk is an application software company that serves industries in architecture, engineering, and construction; product design and manufacturing; and media and entertainment. Autodesk software enables design, modeling, and rendering needs of these industries. The company has over 4 million paid subscribers across 180 countries.
<h3>Breaking Down Autodesk's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Autodesk's remarkable performance in 3M is evident. As of 30 April, 2025, the company achieved an impressive revenue growth rate of 15.24%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 9.31%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Autodesk's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.8%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Autodesk's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.42%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Autodesk's debt-to-equity ratio stands notably higher than the industry average, reaching 0.97. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

ADSK

27 Analysts Assess Autodesk: What You Need To Know

Advanced Energy Indus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEIS#NASDAQ">AEIS</a>) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $131.83, along with a high estimate of $140.00 and a low estimate of $124.00. Witnessing a positive shift, the current average has risen by 0.38% from the previous average price target of $131.33.
<img src="https://www.benzinga.com/files/images/story/2025/1751047296_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Advanced Energy Indus. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Atif Malik</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$140.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Brian Chin</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$130.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$132.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>James Ricchiuti</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$135.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Robert Mason</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$124.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Advanced Energy Indus. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Advanced Energy Indus compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Advanced Energy Indus's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Advanced Energy Indus's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AEIS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Advanced Energy Indus analyst ratings.</a>
<h2>All You Need to Know About Advanced Energy Indus</h2>
Advanced Energy Industries Inc provides precision power-conversion measurement and control solutions that transform power into various forms for use in manufacturing and industrial equipment and applications. The firm serves original equipment manufacturers and end customers in the semiconductor, flat panel display, solar panel, and other industrial capital equipment markets. Products include thin-film power-conversion systems, which control and modify raw electrical power into a customizable, predictable power source, and power control modules, which control and measure temperature during manufacturing cycles. A majority of the firm's revenue is generated in United States, with the rest from Mexico, Taiwan, China and All others.
<h3>Advanced Energy Indus's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Advanced Energy Indus showcased positive performance, achieving a revenue growth rate of 23.54% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: Advanced Energy Indus's net margin excels beyond industry benchmarks, reaching 6.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.03%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Advanced Energy Indus's ROA stands out, surpassing industry averages. With an impressive ROA of 1.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Advanced Energy Indus's debt-to-equity ratio surpasses industry norms, standing at 0.55. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEIS

Forecasting The Future: 6 Analyst Projections For Advanced Energy Indus

Amer Sports shares are trading higher on possible continued strength after Piper Sandler initiated coverage on the stock yesterday with an Overweight rating and announced a price target of $45.

Ratings for NovoCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCR#NASDAQ">NVCR</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $30.75, accompanied by a high estimate of $34.00 and a low estimate of $27.00. Experiencing a 8.21% decline, the current average is now lower than the previous average price target of $33.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1751047276_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of NovoCure among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$34.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NovoCure. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of NovoCure compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for NovoCure's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of NovoCure's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NVCR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on NovoCure analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know NovoCure Better</h2>
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
<h3>Breaking Down NovoCure's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: NovoCure displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 11.91%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: NovoCure's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -22.14%, the company may face hurdles in effective cost management.
Return on Equity (ROE): NovoCure's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -9.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): NovoCure's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.76%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 1.92, NovoCure faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NVCR

Demystifying NovoCure: Insights From 4 Analyst Reviews

Investors with a lot of money to spend have taken a bearish stance on Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NFLX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 155 uncommon options trades for Netflix.
This isn't normal.
The overall sentiment of these big-money traders is split between 32% bullish and 36%, bearish.
Out of all of the special options we uncovered, 35 are puts, for a total amount of $2,917,617, and 120 are calls, for a total amount of $16,220,624.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $10.0 to $2310.0 for Netflix over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Netflix's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Netflix's substantial trades, within a strike price spectrum from $10.0 to $2310.0 over the preceding 30 days.
<h3>Netflix Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751047267_0_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$935.95</td>
<td>$927.9</td>
<td>$932.12</td>
<td>$400.00</td>
<td>$3.4M</td>
<td align="right">186</td>
<td align="right">24</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/17/27</td>
<td>$1319.0</td>
<td>$1309.0</td>
<td>$1309.0</td>
<td>$10.00</td>
<td>$1.0M</td>
<td align="right">11</td>
<td align="right">8</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$932.75</td>
<td>$931.35</td>
<td>$931.36</td>
<td>$400.00</td>
<td>$745.3K</td>
<td align="right">186</td>
<td align="right">23</td>
</tr>
<tr>
<td>NFLX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$935.6</td>
<td>$928.9</td>
<td>$930.95</td>
<td>$400.00</td>
<td>$744.7K</td>
<td align="right">186</td>
<td align="right">8</td>
</tr>
<tr>
<td>NFLX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/17/27</td>
<td>$251.5</td>
<td>$246.7</td>
<td>$248.54</td>
<td>$1320.00</td>
<td>$298.2K</td>
<td align="right">32</td>
<td align="right">19</td>
</tr>
</tbody>
</table>

<h3>About Netflix</h3>
Netflix's relatively simple business model involves only one business, its streaming service. It has the biggest television entertainment subscriber base in both the United States and the collective international market, with more than 300 million subscribers globally. Netflix has exposure to nearly the entire global population outside of China. The firm has traditionally avoided a regular slate of live programming or sports content, instead focusing on on-demand access to episodic television, movies, and documentaries. The firm introduced ad-supported subscription plans in 2022, giving the firm exposure to the advertising market in addition to the subscription fees that have historically accounted for nearly all its revenue.
In light of the recent options history for Netflix, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of Netflix</h3>
<ul>
<li>Trading volume stands at 1,784,414, with NFLX's price up by 0.93%, positioned at $1318.88.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What Analysts Are Saying About Netflix</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $1445.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Netflix, which currently sits at a price target of $1425. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Netflix, which currently sits at a price target of $1450. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Neutral rating on Netflix with a target price of $1250. 
&#x2A; An analyst from Pivotal Research has decided to maintain their Buy rating on Netflix, which currently sits at a price target of $1600. 
&#x2A; An analyst from Wells Fargo persists with their Overweight rating on Netflix, maintaining a target price of $1500. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Netflix with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Comments

Axion Ven

Axion Ven (AXNVF) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL